Nasdaq

Verona Pharma plc : Holding(s) in Company

06-06-2017

For filings with the FCA include the annex For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES ⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Verona Pharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Aisling Capital Management LP Aisling Capital IV LP
4. Full name of shareholder(s) (if different from 3.): ^iv	Aisling Capital IV LP
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	05/19/2017
6. Date on which issuer notified:	05/26/2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	Upward crossing of 3% threshold

8. Notified details:

A: Voting rights attached to shares
^{viii, ix}

Class/type of

shares

if possible using

the ISIN CODE

Situation previous

to the triggering

transaction

Resulting situation after the triggering transaction

Number

of

Shares

Number

of

Voting

Rights

Number

of shares

Number of voting

rights

% of voting rights
^x

Direct

Direct
^xi

Indirect
^xii

Direct

Indirect

Ordinary

ISIN GB00B06GSH43

1,474,688

2,074,080

1.41%

1.98%

ADS

ISIN US9250501064

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial

instrument

Expiration

date

^xiii

Exercise/

Conversion Period

^xiv

Number of voting

rights that may be

acquired if the

instrument is

exercised/ converted.

% of voting

rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial

instrument

Exercise price

Expiration date
^xvii

Exercise/

Conversion period

^xviii

Number of voting rights instrument refers to

% of voting rights
^{xix, xx}

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,548,768

3.38%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
Aisling Capital IV LP (which holds 3,548,768 shares in the Company (3.38%)) is managed by Aisling Capital Management LP.
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:
14. Contact name:	Robert Wenzel
15. Contact telephone number:	212-651-6374

Note: Annex should only be submitted to the FCA not the issuer Annex: Notification of major interests in share (xxii)

A: Identity of the persons or legal entity subject to the notification obligation
Full name (including legal form of legal entities)	Aisling Capital IV LP
Contact address (registered office for legal entities)	888 7 ^th Avenue, 12 ^th floor New York, NY 10106
Phone number & email	212-651-6380 / rwenzel@aislingcapital.com
Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable
Full name
Contact address
Phone number & email
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

*For notes on how to complete form TR-1 please see the FCA website.*

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via GlobeNewswire

HUG#2110748